

Barbara Frigerio

List of Publications by Citations

Source: <https://exaly.com/author-pdf/813656/barbara-frigerio-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

11
papers

136
citations

6
h-index

11
g-index

12
ext. papers

180
ext. citations

6.8
avg, IF

2.05
L-index

#	Paper	IF	Citations
11	A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. <i>European Journal of Cancer</i> , 2013 , 49, 2223-32	7.5	42
10	Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 125	12.8	36
9	Full preclinical validation of the ¹²³ I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging. <i>Oncotarget</i> , 2017 , 8, 10919-10930	3.3	14
8	Anti-PSMA I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 326	12.8	9
7	Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen. <i>Immunology Letters</i> , 2015 , 168, 105-10	4.1	8
6	Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells. <i>MABs</i> , 2018 , 10, 1084-1097	6.6	8
5	A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy. <i>Frontiers in Immunology</i> , 2019 , 10, 2514	8.4	5
4	Broad-spectrum inhibition of HIV-1 by a monoclonal antibody directed against a gp120-induced epitope of CD4. <i>PLoS ONE</i> , 2011 , 6, e22081	3.7	5
3	Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection. <i>Journal of Translational Medicine</i> , 2009 , 7, 101	8.5	4
2	Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody. <i>Cells</i> , 2020 , 9,	7.9	3
1	Soil persistence of DNA from transgenic poplar. <i>Environmental Biosafety Research</i> , 2009 , 8, 79-86		2